Cargando…

The ELISA Detectability and Potency of Pegfilgrastim Decrease in Physiological Conditions: Key Roles for Aggregation and Individual Variability

PEGylated recombinant human granulocyte colony stimulating factor (pegfilgrastim) is used clinically to accelerate immune reconstitution following chemotherapy and is being pursued for biosimilar development. One challenge to overcome in pegfilgrastim biosimilar development is establishing pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Tao, Fang, Hui, Ouyang, Weiming, Angart, Phillip, Chiang, Meng-Jung, Bhirde, Ashwinkumar A., Sheikh, Faruk, Lynch, Patrick, Shah, Ankit B., Patil, Sharadrao M., Chen, Kang, Shen, Meiyu, Agarabi, Cyrus, Donnelly, Raymond P., Brorson, Kurt, Schrieber, Sarah J., Howard, Kristina E., Rogstad, Sarah M., Frucht, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016140/ https://www.ncbi.nlm.nih.gov/pubmed/32051479 http://dx.doi.org/10.1038/s41598-020-59346-z

Ejemplares similares

An etanercept O-glycovariant with enhanced potency
por: Biel, Thomas G., et al.
Publicado: (2022)

Multivariate data analysis of growth medium trends affecting antibody glycosylation
por: Powers, David N., et al.
Publicado: (2019)

Targeted Nanoprobes Reveal Early Time Point Kinetics In Vivo by Time-Resolved MRI
por: Bhirde, Ashwinkumar, et al.
Publicado: (2011)

Hybridoma cell-culture and glycan profile dataset at various bioreactor conditions
por: Bhatia, Hemlata, et al.
Publicado: (2016)

Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics
por: Ouyang, Weiming, et al.
Publicado: (2023)

Role of Albumin in the Formation and Stabilization of Nanoparticle Aggregates in Serum Studied by Continuous Photon Correlation Spectroscopy and Multiscale Computer Simulations
por: Bhirde, Ashwinkumar A., et al.
Publicado: (2014)

Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells
por: Velugula-Yellela, Sai Rashmika, et al.
Publicado: (2018)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

Real‐time quantification and supplementation of bioreactor amino acids to prolong culture time and maintain antibody product quality
por: Powers, David N., et al.
Publicado: (2019)

Pegfilgrastim Biosimilars: Where Are We Now?
por: Selby, Christopher, et al.
Publicado: (2021)

Pegfilgrastim in Supportive Care of Hodgkin Lymphoma
por: Cerchione, Claudio, et al.
Publicado: (2022)

Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies
por: Civoli, Francesca, et al.
Publicado: (2022)

Improved Stability of a Model IgG3 by DoE-Based Evaluation of Buffer Formulations
por: Chavez, Brittany K., et al.
Publicado: (2016)

Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events
por: Fratz‐Berilla, Erica J., et al.
Publicado: (2020)

Relapsing Acute Kidney Injury Associated with Pegfilgrastim
por: Arora, Swati, et al.
Publicado: (2012)

Impacts of intentional mycoplasma contamination on CHO cell bioreactor cultures
por: Fratz‐Berilla, Erica J., et al.
Publicado: (2019)

Safety of Pegfilgrastim (Neulasta) in Patients with Sickle Cell Trait/Anemia
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2013)

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
por: Kang, Ka‐Won, et al.
Publicado: (2020)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

Cyclophosphamide/docetaxel/pegfilgrastim: Various toxicities: case report
Publicado: (2021)

Evaluation of a novel medical device for pegfilgrastim administration
por: Aruga, Tomoyuki, et al.
Publicado: (2022)

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(®) in healthy subjects: A randomized, double‐blind trial
por: Wynne, Chris, et al.
Publicado: (2020)

PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)

Development of an ELISA-Based Potency Assay for Inactivated Influenza Vaccines Using Cross-Reactive Nanobodies
por: Cheung, Chung Y., et al.
Publicado: (2022)

Morphologically-Directed Raman Spectroscopy as an Analytical Method for Subvisible Particle Characterization in Therapeutic Protein Product Quality
por: Kim, Minkyung, et al.
Publicado: (2023)

Assessment of in vitro potency of inactivated Newcastle disease oil-adjuvanted vaccines using hemagglutination test and blocking ELISA
por: Aly, Saleh E., et al.
Publicado: (2018)

An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines
por: Bodle, Jesse, et al.
Publicado: (2023)

Pseudogout Attack after Pegfilgrastim Administration in Anaplastic Large Cell Lymphoma
por: Hatayama, Mayumi, et al.
Publicado: (2018)

Neutrophilic eccrine hidradenitis secondary to pegfilgrastim in a patient with synovial sarcoma
por: Puar, Neha, et al.
Publicado: (2019)

Pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
por: Wessels, Hendrik, et al.
Publicado: (2019)

Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies
por: Brekkan, Ari, et al.
Publicado: (2019)

Development of a C3c-based ELISA method for the determination of anti-complementary potency of Bupleurum polysaccharides
por: Wu, Mulu, et al.
Publicado: (2015)

Initial testing of pegfilgrastim (Neulasta Onpro) on‐body injector in multiple radiological imaging environments
por: Long, Zaiyang, et al.
Publicado: (2021)

Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma
por: Cocorocchio, E, et al.
Publicado: (2010)

Erk1/2 Inactivation-Induced c-Jun Degradation Is Regulated by Protein Phosphatases, UBE2d3, and the C-Terminus of c-Jun
por: Ouyang, Weiming, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
por: Roth, Karsten, et al.
Publicado: (2019)

Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure
por: Cornes, Paul, et al.
Publicado: (2020)

Recurrent Granulocyte Colony-Stimulating Factor-Induced Aortitis After Pegfilgrastim Administration
por: Kawahara, Hiroshi, et al.
Publicado: (2020)

Drug-induced aortitis of the subclavian artery caused by pegfilgrastim: a case report
por: Jimbo, Hikari, et al.
Publicado: (2021)

A Case of Concurrent Leukocytosis and Systemic Capillary Leak Syndrome Due to Pegfilgrastim
por: Gotera, Nico, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i0njlrvb68chc7qsejk87n3m20